Introduction of Appropriate Advanced Technology Sample Clauses

Introduction of Appropriate Advanced Technology. (a) Each of the Parties shall wherever possible introduce to the Joint Venture appropriate advanced equipment, technology and managerial experience necessary for efficient and productive conduct of the Operations. The general manager shall ensure that Joint Venture employees and contractors engaged by the Joint Venture receive training to ensure their comprehension and efficient deployment of such technology and management practice in the context of Operations to be undertaken. (b) The technology transfer envisaged by paragraph 12.4.2 (a) above shall not require either Party capable of transferring technology to disclose or introduce restricted proprietary know-how, patents or other commercially confidential information to the Joint Venture. However, wherever possible a Party which intends to transfer technology shall endeavour to have the Joint Venture licensed to use technology appropriate to the Operations, subject always to the prior approval of the proprietor of such technology. Costs and expenses incurred by the Joint Venture in the course of its personnel training program under sub-sections 12.5.1 and 12.5.2 shall be charged to Project Expenditure.
View SourceView Similar (2)
Introduction of Appropriate Advanced Technology. (a) Each of the Parties shall wherever possible introduce to the Joint Venture appropriate advanced equipment, technology and managerial experience necessary for efficient and productive conduct of the Operations. The Chairman shall ensure that Joint Venture employees and contractors engaged by the Joint Venture receive training to ensure their comprehension and efficient deployment of such technology and management practice in the context of Operations to be undertaken. (b) The technology transfer envisaged by PARAGRAPH 12.4.2 (a) above shall not require either Party capable of transferring technology to disclose or introduce restricted proprietary know-how, patents or other commercially confidential information to the Joint Venture. However, wherever possible a Party which intends to transfer technology shall endeavour to have the Joint Venture licensed to use technology appropriate to the Operations, subject always to the prior approval of the proprietor of such technology costs and expenses incurred by the Joint Venture in the course of its personnel training program under SUB-SECTIONS 12.4.1 and 12.
View Source

Related to Introduction of Appropriate Advanced Technology

  • Scope of Collaboration As part of the collaboration, the Controllers will act as Joint Controller. The roles of the Controller and the associated tasks are specified in more detail in Appendix 1. If one party is solely responsible for a data processing operation, this party will implement all relevant data protection provisions on its own responsibility. However, such data processing procedures are not subject to this Agreement. Joint data processing and the type of Personal Data collected and processed within the framework of collaboration are specified in Appendix 1.

  • Selection of Subcontractors, Procurement of Materials and Leasing of Equipment The contractor shall not discriminate on the grounds of race, color, religion, sex, national origin, age or disability in the selection and retention of subcontractors, including procurement of materials and leases of equipment. The contractor shall take all necessary and reasonable steps to ensure nondiscrimination in the administration of this contract. a. The contractor shall notify all potential subcontractors and suppliers and lessors of their EEO obligations under this contract. b. The contractor will use good faith efforts to ensure subcontractor compliance with their EEO obligations.

  • Human Leukocyte Antigen Testing This plan covers human leukocyte antigen testing for A, B, and DR antigens once per member per lifetime to establish a member’s bone marrow transplantation donor suitability in accordance with R.I. General Law §27-20-36. The testing must be performed in a facility that is: • accredited by the American Association of Blood Banks or its successors; and • licensed under the Clinical Laboratory Improvement Act as it may be amended from time to time. At the time of testing, the person being tested must complete and sign an informed consent form that also authorizes the results of the test to be used for participation in the National Marrow Donor program.

  • Application of Funding Techniques to Programs 6.3.1 The State shall apply the following funding techniques when requesting Federal funds for the component cash flows of the programs listed in sections 4.2 and 4.3 of this Agreement. 6.3.2 Programs Below are programs listed in Section 4.2 and Section 4.3.

  • Orally Administered Anticancer Medication In accordance with RIGL § 27-20-67, prescription drug coverage for orally administered anticancer medications is provided at a level no less favorable than coverage for intravenously administered or injected cancer medications covered under your medical benefit.